Published in Vaccine Weekly, October 10th, 2007
Both DelSite Biotechnologies and ElSohly Laboratories have been beneficiaries in Cooperative Research and Development Agreements (CRADAs) with the National Cancer Institute (NCI). DelSite's CRADA currently covers the development of a nasal powder vaccine for Human Papillomavirus (HPV). ElSohly's CRADA covered an anticancer drug that has demonstrated anticancer activity and reduction of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.